Here at Private Briefing,we do our best to offer consistent follow-up reports on our “best idea” recommendations – including “liquid-biopsy” play TrovaGene Inc. (Nasdaq: TROV).
In the last two weeks alone we’ve delivered several updates on the San Diego-based firm, which we first brought your way back on March 11. And we’ve done at least a dozen total reports along the way.
The stock has really skidded of late – as investors have taken down an array of the stocks perceived as being among the riskiest in the market.
33-year seasoned market analyst and professional trader with highly accurate track record. Specialty in global markets.
35-year expert in oil and gas policy, risk assessment, and emerging market economic development.
30-year CBOE trader, market maker, and retired hedge fund honcho. Helped launch the Volatility Index in 1993.
30-year veteran of tech markets with a Rolodex of Silicon Valley CEOs. Pulitzer nominee. Uncovered rare earths crisis.
30-year veteran analyst of business, economics, and financial markets. Award-winning author of "Contrarian Investing."
Known for his pioneering research on the seven "sparks" that trigger explosive profits in the small-cap sector.
Gifted researcher with 20 years' experience tracking bioscience and pharma stocks. Master of the FDA approval process.
Nationally recognized technical trader. Background in engineering, system designs, and risk reduction. 26 years in the markets.
Top money manager for 25 years. Leading credit market analyst. Best-known for calling the major recent global market moves.
Tom Gentile is one of the world's foremost authorities on stock, futures and options trading.